Forte Biosciences, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense
Impairment of property and equipment
Accretion of debt discount on available-for-sale securities
Stock-based compensation expense

Changes in operating assets and liabilities:
Prepaid expenses and other assets
Accounts payable
Accrued liabilities
Income taxes payable
Net cash used in operating activities
Cash flows from investing activities:
Purchase of available-for-sale securities
Proceeds from maturity of available-for-sale securities
Proceeds from redemptions of short-term investments
Purchase of property and equipment
Net cash provided by (used in) investing activities
Cash flows from financing activities:
Proceeds from issuance of common stock and pre-funded warrants
Payment of issuance costs associated with financings
Proceeds from exercise of employee stock options and issuance of common stock under ESPP
Proceeds from issuance of common stock upon exercise of underwriters' option
Proceeds from exercise of stock options
Proceeds from exercise of employee stock options and ESPP
Proceeds from issuance of common stock under ESPP
Proceeds from exercise of warrants and options
Taxes paid related to net share settlement of equity awards
Settlement of fractional shares paid in cash
Net cash provided by financing activities

Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents - beginning of year
Cash and cash equivalents - end of year
Supplemental disclosure of non-cash investing and financing activities:
Unpaid issuance costs recorded in accounts payable and accrued liabilities
Purchase of property and equipment recorded in accrued liabilities

Comments